T1	intervention 115 135	oxidized mannan-MUC1
T2	outcome 939 954	recurrence rate
T3	control 977 984	placebo
T4	cv-bin-percent 989 992	60%
T5	cv-bin-abs 994 998	nine
T6	control-participants 1002 1004	15
T7	iv-bin-percent 1061 1066	12.5%
T8	iv-bin-abs 1068 1071	two
T9	intervention-participants 1075 1077	16
T10	outcome 1084 1102	time of recurrence
T11	cv-cont-mean 1159 1170	65.8 months
T12	iv-cont-mean 1270 1280	118 months
T13	eligibility 630 673	breast cancer patients vaccinated with M-FP
T14	outcome 1222 1241	recurrence appeared
T15	outcome 1474 1487	toxic effects
T16	outcome 1612 1628	overall survival
